Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)
Sponsor: Dartmouth-Hitchcock Medical Center
Terminated
low accrual not allowing site to meeting statistical endpoints
Other terminated trials from Dartmouth-Hitchcock Medical Center
- Anaplastic Astrocytoma · Aug 2025
- Lumbar Puncture · Phase NA · Dec 2023
- Vaccine Hesitancy · Phase NA · Jul 2023
- Pituitary Macroadenoma · Phase NA · Jul 2023
- Depression, Bipolar · Phase NA · Sep 2022
See all terminations from Dartmouth-Hitchcock Medical Center
Other Metastatic Renal Cell Carcinoma trials with similar outcome
Listed as NCT00913913, this PHASE2 trial focuses on Metastatic Renal Cell Carcinoma and remains terminated or withdrawn. Sponsored by Dartmouth-Hitchcock Medical Center, it has been updated 9 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth-Hitchcock Medical Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .